Alnylam's Nucapsiran: RNAi for Hypertension Could Disrupt a $30B Market

Alnylam Pharmaceuticals is best known for RNAi therapies for rare diseases (Onpattro, Givlaari, Oxlumo). But nucapsiran could be the drug that takes RNAi into a mass market: hypertension.

The concept

Nucapsiran is an RNAi therapeutic that silences the angiotensinogen gene in the liver. Angiotensinogen is the precursor to angiotensin II, the hormone that constricts blood vessels and raises blood pressure. By reducing angiotensinogen production, nucapsiran lowers blood pressure at the source.

The differentiator: duration. Current hypertension drugs (ACE inhibitors, ARBs) need to be taken daily. Nucapsiran is dosed quarterly — four injections per year instead of 365 pills.

The data

The Phase 1 trial in 80 patients with mild-to-moderate hypertension showed:

• Systolic BP reduction: -18 mmHg at 3 months (single dose)
• Duration: Effect sustained for 6+ months after a single dose
• Safety: No serious adverse events, no orthostatic hypotension

The Phase 2 trial (KARDIA-1) is enrolling 400 patients and will report data in Q4 2026. The primary endpoint is change in 24-hour ambulatory systolic blood pressure at 3 months.

The market

Hypertension is a $30 billion global market. Over 1 billion people worldwide have high blood pressure, and adherence to daily medication is notoriously poor (50% of patients stop taking their pills within a year).

A quarterly injection could solve the adherence problem — and command a premium price. If nucapsiran is approved for resistant hypertension (patients who fail on 3+ drugs), the initial market is 10 million patients in the US alone. Peak sales estimates range from $2–5 billion.

The broader opportunity: if safety data supports it, nucapsiran could expand to first-line hypertension. That’s a $10B+ opportunity.

The risk

This is a Phase 2 asset. Phase 2 is the proof-of-concept stage — the data could be positive, negative, or ambiguous. If KARDIA-1 misses its primary endpoint, nucapsiran’s value drops to near zero.

The safety question is also open. Long-term angiotensinogen suppression could have effects beyond blood pressure. The FDA will want to see safety data over 12+ months before approving a drug that patients will take for decades.

What we’re watching

1. KARDIA-1 Phase 2 data (Q4 2026): The binary event. Positive data could add $2–3B to Alnylam’s market cap.
2. Cemdisiran PDUFA (September 28): Alnylam’s complement drug has a PDUFA date first. Approval validates the RNAi platform.
3. Phase 3 design: If KARDIA-1 is positive, Phase 3 will start in 2027. The trial size and duration will tell us the timeline to approval.
4. Partnership: Alnylam may partner nucapsiran for the mass-market hypertension opportunity — a deal with a big pharma would validate the asset.

Alnylam is up 20% YTD, and nucapsiran is a big reason why. The Q4 data readout is the next major catalyst.